Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
:BLRX
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.35Last Year’s EPS
0Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 27, 2025
|% Change Since: 48.63%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with significant achievements in licensing agreements, financial efficiency, and promising clinical trial results in pancreatic cancer. However, there were challenges in revenue generation due to the transition of APHEXDA sales and ongoing efforts to acquire new assets without a definitive outcome yet.Company Guidance
During BioLineRx's Q1 2025 financial results call, the company highlighted several key metrics and strategic moves. The partnership with Ayrmid Pharma Limited, which started in 2024, resulted in $1.4 million in APHEXDA sales for Q1 2025, generating $0.3 million in royalty revenue for BioLineRx. The company's financials showed a significant reduction in operating expenses, with operating cash burn reduced by over 70% from $40 million to under $12 million annually, following a restructuring that included a headcount reduction and the shutdown of U.S. operations. BioLineRx ended the quarter with $26.4 million in cash, with a runway expected to last through the second half of 2026. The call detailed ongoing clinical developments, including a Phase 2b study of motixafortide in pancreatic cancer, with a planned interim analysis in 2026. The company continues to evaluate potential in-licensing opportunities to expand its pipeline, leveraging expertise in oncology and rare diseases.Transformational Licensing Agreement with Ayrmid Pharma
Exclusive out-licensing agreement for APHEXDA with Ayrmid Pharma Limited, including upfront payment, significant commercial milestones, and royalties.
Significant Reduction in Operating Cash Burn
Reduced ongoing operating cash burn by over 70% from $40 million to less than $12 million annually.
Positive Financial Position
Net income of $5.1 million for Q1 2025, compared to a net loss of $0.7 million in Q1 2024, primarily due to non-operating income from the revaluation of warrants.
Strong Performance in Pancreatic Cancer Studies
Promising results from CheMo4METPANC trial, including a partial response rate of 64% and a disease control rate of 91%, with some patients showing significant long-term progression-free survival.
Encouraging APHEXDA Sales Under Ayrmid
APHEXDA sales generated $1.4 million in Q1 2025, resulting in $0.3 million of royalty revenues to BioLineRx.
Robust Cash Position
Ended Q1 2025 with $26.4 million in cash, cash equivalents, and short-term bank deposits, with a cash runway projected through the second half of 2026.
BLRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BLRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 27, 2025 | $3.66 | $3.68 | +0.55% |
Mar 31, 2025 | $3.05 | $2.96 | -2.95% |
Nov 25, 2024 | $11.12 | $10.87 | -2.25% |
Aug 15, 2024 | $31.00 | $27.13 | -12.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bioline RX Ltd Sponsored ADR (BLRX) report earnings?
Bioline RX Ltd Sponsored ADR (BLRX) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Bioline RX Ltd Sponsored ADR (BLRX) earnings time?
Bioline RX Ltd Sponsored ADR (BLRX) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLRX EPS forecast?
BLRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.35.